Dextenza (Dexamethasone) Patent Expiration, LOE Window & CMS Spending

Dextenza (Dexamethasone) by Ocular Therapeutix: FDA Orange Book LOE 2041-04-26, 15 AB generics, $1.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOcular Therapeutix
FDA Application & PathwayN208742 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-04-26
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors15
2024 CMS Total Public Spend$1.4M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel